Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

Exclusive Licenses Do Not Discourage Follow On Research


A recent study presented at the Patent Statistics for Decision Makers Conference organized at the United States Patent Office questions the logic behind a nonexclusive license preference often found in U.S. government technology transfer policy. In “The Role of Exclusive Licensing in Follow-on Research of Academic Patented Inventions” presentation the authors demonstrate that, contrary to the belief by some, exclusive licensing does not impede future research. The authors ask two questions.  First, does exclusive licensing affect licensee follow-on research?  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO’s Prometheus v. Mayo Amicus Brief Filed


BIO filed an amicus brief in the Prometheus v. Mayo Clinic case.  In this case the Supreme Court is being asked to decide whether diagnostic and personalized medicine claims that depend on a correlation of observed phenomena should be excluded from the patent system at the outset, as patent-ineligible abstract ideas or “laws of nature.” BIO’s brief argues that these judicially-created exclusions from patent-eligibility have traditionally been used only under narrow circumstances, and that their Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

EU Stem Cell Patent Decision Hurts Science


A great article in the Economist titled European science stemmed addresses the recent and controversial decision by the European Court of Justice regarding the patentability of certain inventions derived from embryonic stem cells. ANY country, you might think, would relish being able to call itself the world’s leader in scientific research. America and Europe, however, seem to be in a bizarre parallel contest: which can make its scientists’ lives more difficult by imposing the most muddled Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Australian Senate Committee Recommends Against Banning ‘Gene Patents’

Australian Parliament House

The Australian Senate Legal and Constitutional Affairs Legislation Committee recommended against the Patent Amendment (Human Genes and Biological Materials) which would have banned DNA patents in Australia.  The push by members of the Australian Senate seemed to mirror efforts in the United States surrounding the Myriad case. The Committee found that: “While previous inquiries and public discussions have focused on the patenting of human genes, the Bill goes further and proposes a specific exclusion for biological materials which Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Technology Transfer Symposium in San Francisco


In the midst of turbulent economic times, and at a moment when the U.S. is looking to encourage technology job creation in the coming decade, an increasing number of public and private sector initiatives have been proposed to spur job creation. While the U.S. leads in the area of biotechnology, there is no guarantee that this competitive edge will continue.  Moreover, although the U.S. is more prolific in life science discoveries than any other single country in the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,